BSH 2017 | New trials in relapsed high-grade lymphomas
Graham Collins
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, from the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses new clinical trials in relapsed high-grade lymphomas at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He speaks about a planned trial of the PD-1 inhibitor nivolumab as a bridge to stem cell transplantation in relapsed Hodgkin Lymphoma. In high-grade lymphoma, Dr Collins is running the TORCH trial (NCT02752204) of the next-generation mTOR inhibitor vistuserib in relapsed diffuse large B-cell lymphoma. He also highlights the potential of rational combination therapies in relapsed high-grade lymphomas.
Related videos
1:27
A historical transition in cancer therapy
Christian Chabannon
1:55
The role of the EBMT regarding CAR T-cell therapy
Christian Chabannon
2:52
CAR T-cell therapy from a hospital perspective
Christian Chabannon
1:27
Integration of CAR T-cell therapy: working with industry
Graham Collins
1:32
CAR T-cell therapy: the importance of LTFU
Graham Collins
